Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data

Basit Öğe Kaydı
dc.authoridkucuksahin, orhan/0000-0003-4530-2304
dc.contributor.authorKalyoncu, U.
dc.contributor.authorBilgin, E.
dc.contributor.authorErden, A.
dc.contributor.authorSatis, H.
dc.contributor.authorTufan, A.
dc.contributor.authorTekgoz, E.
dc.contributor.authorAtes, A.
dc.date.accessioned2024-09-18T21:00:20Z
dc.date.available2024-09-18T21:00:20Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is a major concern in RA. These patients have been included in clinical trials and in the post-marketing setting of RA patients using tofacitinib. We aimed to assess the real-life efficacy and safety of tofacitinib in patients with RA-ILD.Methods RA patients with ILD diagnosis based on the HRCT images of the lungs from eight different centres recruited to study. As a control group, RA patients without ILD under tofacitinib were included. Demographic data, patients' characteristics, available pulmonary function tests regarding RA and RA-ILD at the visit in which tofacitinib was initiated and for the last follow-up visit under tofacitinib were recorded. Reasons for tofacitinib discontinuation were also recorded. Drug retention rates were compared by log-rank test. p-value <0.05 was considered statistically significant.Results A total of 47(42.6% male) RA patients with RA-ILD and a control group of 387 (17.8% male) patients without RA-ILD were included in analysis. After the median of 12 (9-19) months follow-up, mean FEV1%; 82.1 vs. 82.8 (pre/post-treatment, respectively, p=0.08), mean FVC%; 79.8 vs. 82.8 (pre/post-treatment, respectively, p=0.014) were stable and worsening was observed in 2/18 (11.1%) patients. Retention rates were similar (p=0.21, log-rank). In RA-ILD group, the most common cause of drug discontinuation was infections (6.3 vs. 2.4 per 100 patient-years).Conclusion Treatment strategy of RA-ILD patients is still based on small observational studies. A high rate of discontinuation due to infections was observed in RA-ILD patients under tofacitinib; however, RA-ILD patients were older than RA patients without ILD.en_US
dc.description.sponsorshipHacettepe Rheumatology Society; Pfizeren_US
dc.description.sponsorshipthe Treasure Registry was funded by Hacettepe Rheumatology Society. This study was funded by Pfizer.en_US
dc.identifier.endpage2077en_US
dc.identifier.issn0392-856X
dc.identifier.issn1593-098X
dc.identifier.issue11en_US
dc.identifier.pmid35084323en_US
dc.identifier.scopus2-s2.0-85133304948en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2071en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/12596
dc.identifier.volume40en_US
dc.identifier.wosWOS:000954898300009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherClinical & Exper Rheumatologyen_US
dc.relation.ispartofClinical and Experimental Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecttofacitiniben_US
dc.subjectrheumatoid arthritisen_US
dc.subjectinterstitial lung diseaseen_US
dc.titleEffectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life dataen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu